COVID19Check-NAS
Antigenic Rapid Test - Nasal sample
Multi-G's Covid19Check-NAS Antigenic Rapid Test for COVID-19 is used to qualitatively detect SARS-CoV-2 antigen in nasal samples.
It is non invasive and painless. It allows easy and hassle free repeated routine testing. Covid19Check-NAS detects the known UK,. Brazil, South Africa and Indian variants of the Sars-Cov-2 virus.
It is non invasive and painless. It allows easy and hassle free repeated routine testing. Covid19Check-NAS detects the known UK,. Brazil, South Africa and Indian variants of the Sars-Cov-2 virus.
The test
There is a critical, global need for rapid antigen test that can complement nucleic acid (PCR) tests for diagnosing SARS-CoV-2 infection. Although critically important, PCR tests are not always available and can last too long in obtaining the result due to the large amount of people who need testing.
Additionally there is growing concern about the acceptability of the very uncomfortable nasopharyngeal swab sampling, especially as testing it is becoming more frequent to secure most daily activities.
Covid19Check-NAS is an efficient and reliable solution to detect infection in cases where the viral load is significant (Ct <33) and the person is likely to be contagious.
Covid19Check-NAS is not only painless and hassle free, but also has a sensitivity of 99% for Ct values up to 33 (the CDC suggests that when the Ct value is >33, the subject is not contagious anymore).
It is particularly useful in cases where frequent testing is required.
The assay can be used as a bedside tool, in a laboratory, a public screening center or used in a general practitioner’s office.
Covid19Check-NAS detects the known variants of the Sars-Cov-2 virus: Lineage B.1.1.7 / 20I/501Y.V1 (UK variant), 484K.V2 (Brazilian variant), 501Y.V2 (South African variant) and B.1.617 (Indian variant).
Covid19Check-NAS detects the known variants of the Sars-Cov-2 virus: Lineage B.1.1.7 / 20I/501Y.V1 (UK variant), 484K.V2 (Brazilian variant), 501Y.V2 (South African variant) and B.1.617 (Indian variant).
COVID19Check-NAS has been validated by the Belgian Health authority (AFMPS/FAGG): https://www.afmps.be/sites/default/files/content/Belgian%20validation.xlsx
This test kit is for healthcare professional use only.
Features & Benefits
Multi-G's Covid19Check-NAS Antigenic Rapid Test for COVID-19 is used to qualitatively detect SARS-CoV-2 virus in nasal samples.
Precise results
- Sensitivity / PPA : 98.1%
- Sensitivity / PPA (Ct ≤33): 99%
- Specificity / NPA : 99.2%
- Total coincidence rate : 99%
Quick & intuitive feedback
- 20 minutes (max.) per test
- Painless (only 2.5cm into the nostril)
- No training needed (vs nasopharyngeal)
- Intuitive visual interpretation
- No special equipment needed
How it works (video available)
The procedure is painless and hassle free compared to a nasopharyngeal test:
Tutorial video in French: https://youtu.be/kwns3bBnwRk
Tutorial video in Dutch: https://youtu.be/s4j7jK9H_sg
Results
A total of two detection lines are possible: one test line, which shows a positive result (even is the line is faint), and the control (C) line acting as a quality control procedure, showing that the sample has flowed through the cassette and the test has worked properly.
Negative
Positive
Performance
Multi-G's Covid19Check-NAS was evaluated in a large clinical study with 492 samples, 107 positive and 385 negative. In that study, Multi-G's Covid19Check-NAS displayed a sensitivity of 98.13% (as high as 99% for Ct values <30) and a specificity of 99.22%.
Covid19Check-NAS shows no cross reaction with a list of 20 common pathogens (H1N1 (new type A H1N1 influenza virus (2009), seasonal H1N1 influenza virus), H3N2, H5N1, H7N9, influenza B Yamagata, Victoria, respiratory syncytial virus, rhinovirus groups A, B, and C, adenovirus 1, Types 2, 3, 4, 5, 7, 55, enterovirus groups A, B, C, D, Epstein‐Barr virus, measles virus, human cytomegalovirus, rotavirus, norovirus, mumps virus, varicella‐band Herpes virus. No interference were found with 15 substances such as Mucin, Hemoglobin, Histamine Hydrochloride , Human albumin , α‐ interferon , Lopinavir , Tobramycin, Ribavirin , Tramadol, Azithromycin, Meropenem, Oseltamivir, Benzocaine, Peramivir.
Covid19Check-NAS shows no cross reaction with a list of 20 common pathogens (H1N1 (new type A H1N1 influenza virus (2009), seasonal H1N1 influenza virus), H3N2, H5N1, H7N9, influenza B Yamagata, Victoria, respiratory syncytial virus, rhinovirus groups A, B, and C, adenovirus 1, Types 2, 3, 4, 5, 7, 55, enterovirus groups A, B, C, D, Epstein‐Barr virus, measles virus, human cytomegalovirus, rotavirus, norovirus, mumps virus, varicella‐band Herpes virus. No interference were found with 15 substances such as Mucin, Hemoglobin, Histamine Hydrochloride , Human albumin , α‐ interferon , Lopinavir , Tobramycin, Ribavirin , Tramadol, Azithromycin, Meropenem, Oseltamivir, Benzocaine, Peramivir.
Quality standards
- In order to ensure the highest level of quality and reliability, Multi-G manufactures its test devices in Belgium, unlike most competitors who simply rebrand Asian made tests.
- Multi-G's Covid19Check-NAS is compliant with the current CE-IVD regulations.
- Multi-G's production facility in Antwerp, Belgium, is LQRA ISO 13485:2016 certified.
- The production facility operates at the highest pharmaceutical standards.
Applications
Multi-G's Covid19Check-NAS covers a range of applications. It allows you to speed up and scale up Covid-19 testing. it is an efficient solution to allow safe professional, business, educational and sports activities.
It is suited for a variety of settings such as companies, pharmacies, airports, schools, universities, sports premises etc.
It is meant for health professionals only.
It is suited for a variety of settings such as companies, pharmacies, airports, schools, universities, sports premises etc.
It is meant for health professionals only.
PCR labs
Reduce the workload of PCR labs, use PCR only to verify positive cases.
Cost reduction
Reduce the cost of testing : Ag Rapid test is on average 8 times cheaper than PCR.
Workplace security
Secure the workplace.
Public spaces
Secure public transports, schools, universities, events etc.
Private events
Screening participants to secure private events (weddings, conferences, exhibitions, etc).
Economic recovery
Accelerate economic recovery by allowing eligible businesses to reopen with screening measures.
